Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs
The Safety and Efficacy of ProHance® at the Dose of 0.10 mmol/kg in Magnetic Resonance Imaging of the Central Nervous System in Pediatric Patients Who Are Younger Than 2 Years of Age
Sponsor: Bracco Diagnostics, Inc
Listed as NCT03750188, this observational or N/A phase trial focuses on Central Nervous System Diseases and Central Nervous System Neoplasms and remains completed. Sponsored by Bracco Diagnostics, Inc, it has been updated 5 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Feb 2020 — Jan 2021 [monthly]
Completed
Status: Recruiting → Completed
-
Dec 2018 — Feb 2020 [monthly]
Recruiting
First recorded
Nov 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bracco Diagnostics, Inc
For direct contact, visit the study record on ClinicalTrials.gov .